Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Assigned Patent

12/31/2013 | 03:06am US/Eastern

By Targeted News Service

ALEXANDRIA, Va., Dec. 31 -- Regeneron Pharmaceuticals, Tarrytown, N.Y., has been assigned a patent (8,613,927) developed by five co-inventors for a "high affinity human antibodies to human nerve growth factor." The co-inventors are Lynn MacDonald, White Plains, N.Y., Richard Torres, New York, Marc R. Morra, Beacon Falls, Conn., Joel H. Martin, Putnam Valley, N.Y., and Joel C. Reinhardt, Mount Kisco, N.Y.

The patent application was filed on Feb. 28, 2012 (13/406,734). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=3&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=141&f=G&l=50&co1=AND&d=PTXT&s1=20131224.PD.&s2=%28NY.ASST.%29&OS=ISD/12/24/2013+AND+AS/NY&RS=ISD/12/24/2013+AND+AS/NY

Written by Sudarshan Harpal; edited by Jaya Anand.

SH1231JA1231-963857

© Targeted News Service, Acquiremedia 2014
React to this article
Latest news on REGENERON PHARMACEUTICALS
9h ago REGENERON PHARMACEUTICALS : Announces Presentation and Panel Discussion at the 3..
2d ago REGENERON PHARMACEUTICALS : "Methods for Treating Allergy and Enhancing Allergen..
4d ago REGENERON PHARMACEUTICALS : Have You Been Counted? Regeneron and Sanofi US Join ..
12/10 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Accepted for Priority R..
12/10 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/05 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/04 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Producing Hybrid Antibo..
12/03 REGENERON PHARMACEUTICALS : and Sanofi Announce that Dupilumab Has Received FDA ..
12/01 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Accepted for Priority..
11/27 REGENERON PHARMACEUTICALS : Assigned Patent
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF